<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049902</url>
  </required_header>
  <id_info>
    <org_study_id>2021-SDU-QILU-G001-2</org_study_id>
    <nct_id>NCT05049902</nct_id>
  </id_info>
  <brief_title>Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication</brief_title>
  <official_title>Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maternity and Child Care Health Center of Dezhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heze Municipal 3rd people's hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PKUcare luzhong hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The researchers collect treatment-naive H.pylori-positive patients from the outpatient&#xD;
      clinic. The subjects were randomized to receive a 10-day or 14-day course of quadruple&#xD;
      eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath&#xD;
      test. Calculate the eradication rates, adverse reaction rates, patient compliance and&#xD;
      cost-effectiveness index of each group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The researchers collect treatment-naive H.pylori-positive patients from the outpatient&#xD;
      clinic. If the subject meets the selection criteria but not the exclusion criteria, and signs&#xD;
      an informed consent form, the researchers randomized the subjects in groups: subjects&#xD;
      received a 10-day or 14-day course of bismuth-containing quadruple eradication therapy. The&#xD;
      medication of groups are as follows. 6-8 weeks after the eradication treatment, the subjects&#xD;
      will review the 13C-urea breath test, and the researcher records the results.&#xD;
&#xD;
      After all subjects were tested, the eradication rates, adverse reaction rates, patient&#xD;
      compliance and cost-effectiveness index of each group were calculated.&#xD;
&#xD;
      According to the course of treatment, it is randomized into a 10-day treatment group and a&#xD;
      14-day treatment group. The two groups of bismuth quadruple regimens are the same, as&#xD;
      follows:&#xD;
&#xD;
      Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin&#xD;
      + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole +&#xD;
      Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's&#xD;
      situation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This trial is a multi-center, open-label, non-inferiority, randomized controlled trial.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate</measure>
    <time_frame>Immediately after follow-up check.</time_frame>
    <description>Both intention to treat (ITT) and per-protocol (PP) analyses will be used for the assessment of the eradication rates of Helicobacter pylori infections in two groups. The ITT analysis includes all randomly assigned patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse reactions</measure>
    <time_frame>Immediately after follow-up check.</time_frame>
    <description>Rate of adverse reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>Immediately after follow-up check.</time_frame>
    <description>Good compliance is defined as the actual dosage is within the range of 80%-100% of the dosage that should be taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness index</measure>
    <time_frame>Immediately after follow-up check.</time_frame>
    <description>Ratio of costs to effectiveness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use the following drug combination option for 10 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.&#xD;
The dosage of each drug is:&#xD;
Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>14-day treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Use the following drug combination option for 14 days. Option 1: Amoxicillin + Clarithromycin + Bismuth + Vonoprazan fumarate Option 2: Amoxicillin + Tetracycline + Bismuth + Vonoprazan fumarate Option 3: Amoxicillin + Metronidazole + Bismuth + Vonoprazan fumarate Three options are selected according to the hospital's situation.&#xD;
The dosage of each drug is:&#xD;
Amoxicillin (Amoxicillin, United Laboratories Co., Ltd.) 1000mg bid Clarithromycin (Klacid, Abbott S.r.l) 500mg bid Tetracycline 500mg qid Metronidazole400mg qid Bismuth Potassium Citrate (Livzon Pharmaceutical Group Inc.) 220mg bid Colloidal Bismuth Pectin (North China Pharmaceutical Co., Ltd.) 200mg bid Vonoprazan fumarate (VOCINTI, Takeda Pharmaceutical Company Limited, Hikari Plant) 20mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clarithromycin</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth Potassium Citrate</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colloidal Bismuth Pectin</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan fumarate</intervention_name>
    <description>Use according to the drug combination options selected by each center.</description>
    <arm_group_label>10-day treatment group</arm_group_label>
    <arm_group_label>14-day treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 18-65.&#xD;
&#xD;
          -  Patients with H.pylori infection (Positive for any of the following: H.pylori culture,&#xD;
             histopathology test, rapid urease test, 13C/14C-urea breath test, stool H.pylori&#xD;
             antigen test).&#xD;
&#xD;
          -  Patients who have never received H. pylori eradication treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with serious underlying diseases, such as liver insufficiency (Aspartate&#xD;
             aminotransferase or alanine aminotransferase greater than 3 times the normal value),&#xD;
             renal insufficiency (Cr≥2.0mg/dL or glomerular filtration rate &lt;50 ml/min),&#xD;
             immunosuppression, malignant tumors, Coronary heart disease or coronary artery&#xD;
             stenosis ≥75%.&#xD;
&#xD;
          -  Patients who are pregnant or lactating or unwilling to take contraceptive measures&#xD;
             during the trial.&#xD;
&#xD;
          -  Patients with active gastrointestinal bleeding.&#xD;
&#xD;
          -  Patients with a history of upper gastrointestinal surgery.&#xD;
&#xD;
          -  Patients allergic to treatment drugs.&#xD;
&#xD;
          -  Patients with medication history of bismuth agents, antibiotics, proton pump inhibitor&#xD;
             and other drugs within 4 weeks&#xD;
&#xD;
          -  Patients with other behaviors that may increase the risk of illness, such as alcohol&#xD;
             and drug abuse&#xD;
&#xD;
          -  Patients whose re-check 13C/14C-urea breath test is negative before the start of the&#xD;
             test.&#xD;
&#xD;
          -  Patients who are unwilling or incapable to provide informed consents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <phone_ext>15588818685</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Ye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maternity and Child Care Health Center of Dezhou</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhi Wang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Heze Municipal 3rd people's hospital</name>
      <address>
        <city>Heze</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fenglan Zhang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu hosipital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>PKUCare Luzhong Hospital</name>
      <address>
        <city>Zibo</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ning Sun</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017 Aug;153(2):420-429. doi: 10.1053/j.gastro.2017.04.022. Epub 2017 Apr 27. Review.</citation>
    <PMID>28456631</PMID>
  </reference>
  <reference>
    <citation>Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, Chen Y, Wang JB, Du YQ, Lu NH; Chinese Society of Gastroenterology, Chinese Study Group on Helicobacter pylori and Peptic Ulcer. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018 Apr;23(2):e12475. doi: 10.1111/hel.12475. Epub 2018 Mar 7.</citation>
    <PMID>29512258</PMID>
  </reference>
  <reference>
    <citation>Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288. Epub 2016 Oct 5.</citation>
    <PMID>27707777</PMID>
  </reference>
  <reference>
    <citation>Liou JM, Malfertheiner P, Lee YC, Sheu BS, Sugano K, Cheng HC, Yeoh KG, Hsu PI, Goh KL, Mahachai V, Gotoda T, Chang WL, Chen MJ, Chiang TH, Chen CC, Wu CY, Leow AH, Wu JY, Wu DC, Hong TC, Lu H, Yamaoka Y, Megraud F, Chan FKL, Sung JJ, Lin JT, Graham DY, Wu MS, El-Omar EM; Asian Pacific Alliance on Helicobacter and Microbiota (APAHAM). Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 Dec;69(12):2093-2112. doi: 10.1136/gutjnl-2020-322368. Epub 2020 Oct 1.</citation>
    <PMID>33004546</PMID>
  </reference>
  <reference>
    <citation>Dore MP, Farina V, Cuccu M, Mameli L, Massarelli G, Graham DY. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter. 2011 Aug;16(4):295-300. doi: 10.1111/j.1523-5378.2011.00857.x.</citation>
    <PMID>21762269</PMID>
  </reference>
  <reference>
    <citation>Rowland M, Daly L, Vaughan M, Higgins A, Bourke B, Drumm B. Age-specific incidence of Helicobacter pylori. Gastroenterology. 2006 Jan;130(1):65-72; quiz 211.</citation>
    <PMID>16401469</PMID>
  </reference>
  <reference>
    <citation>O'Ryan ML, Rabello M, Cortés H, Lucero Y, Peña A, Torres JP. Dynamics of Helicobacter pylori detection in stools during the first 5 years of life in Chile, a rapidly developing country. Pediatr Infect Dis J. 2013 Feb;32(2):99-103. doi: 10.1097/INF.0b013e318278b929.</citation>
    <PMID>23076385</PMID>
  </reference>
  <reference>
    <citation>Qiao C, Li Y, Liu J, Ji C, Qu J, Hu J, Ji R, Wan M, Lin B, Lin M, Qi Q, Zuo X, Li Y. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol. 2021 Sep;36(9):2383-2388. doi: 10.1111/jgh.15468. Epub 2021 Mar 10.</citation>
    <PMID>33691344</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 5, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>Director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>Helicobacter pylori</keyword>
  <keyword>Bismuth-containing quadruple regimen</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Potassium Citrate</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

